Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data

References

• AmbrosioniEBorghiCMagnaniBfor the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study InvestigatorsThe effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarctionN Engl J Med19953338057990904
   PubMed Web of Science ®Google Scholar
• AmbrosioniELeonettiGPessinaACPatterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive TherapyJ Hypertens2000181691911081785
   PubMed Web of Science ®Google Scholar
• BorghiCAmbrosioniEZofenopril: A review of the evidence of its benefits in hypertension and acute myocardial infarctionClin Drug Invest20002037184
   Web of Science ®Google Scholar
• BorghiCAmbrosioniESurvival of Myocardial Infarction Long-term Evaluation-2 Working PartyDouble-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) studyAm Heart J200314580712514658
   PubMed Web of Science ®Google Scholar
• BorghiCBacchelliSDegli EspostiDA review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseasesExpert Opin Pharmacother2004519657715330734
   PubMed Web of Science ®Google Scholar
• BorghiCBacchelliSEspostiDDSMILE StudyEffects of the early ACE inhibition in diabetic non-thrombolyzed patients with anterior acute myocardial infarctionDiabetes Care2003261862812766124
   PubMed Web of Science ®Google Scholar
• CollinsRMacMahonSBlood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart diseaseBr Med Bull199450272988205459
   PubMed Web of Science ®Google Scholar
• CushmanDWCheungHSSaboEFDesign of potent competitive inhibition of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acidsBiochemistry197716548491200262
   PubMed Web of Science ®Google Scholar
• DzauVThe cardiovascular continuum and renin-angiotensin-aldosterone system blockadeJ Hypertens200523Suppl 1S9S17
   Google Scholar
• [ESH–ESC] European Society of Hypertension – European Society of Cardiology Guidelines Committee2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertensionJ Hypertens20032110115312777938
   PubMed Web of Science ®Google Scholar
• [EUROASPIRE II] EUROASPIRE II Euro Heart Survey ProgrammeLifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey ProgrammeEur Heart J2001225547211259143
   PubMed Web of Science ®Google Scholar
• EvangelistaSManziniSAntioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenoprilJ Int Med Res200533425415651714
   PubMed Web of Science ®Google Scholar
• EzzatiMLopezADRodgersASelected major risk factors and global and regional burden of diseaseLancet200236013476012423980
   PubMed Web of Science ®Google Scholar
• FranklinSLarsonMGKhanSADoes the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart StudyCirculation20011031245911238268
   PubMed Web of Science ®Google Scholar
• FrascarelliSGhelardoniSRonca-TestoniSCardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusionJ Cardiovasc Pharmacol200443294914716220
   PubMed Web of Science ®Google Scholar
• GagnonCLegaultFGeraldesPDiverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive ratsInt J Cardiol2004973738115561321
   PubMed Web of Science ®Google Scholar
• García-EstanJOrtizCO’ValleFEffects of angiotensin converting enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide deficiency induced hypertension in ratsClin Sci20061102273316197366
   PubMed Web of Science ®Google Scholar
• GavrasIRosenthalTCombination therapy as first-line treatment for hypertensionCurr Hypertens Rep200462677215257860
   PubMed Web of Science ®Google Scholar
• GiatrasILauJLeveyASEffect of angiotensin-converting-enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trialsAnn Intern Med1997127337459273824
   PubMed Web of Science ®Google Scholar
• HajjarIKotchenTATrends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000J Am Med Assoc2003290199206
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiAfor the HOT Study GroupThe Hypertension Optimal Treatment (HOT) study: 24-month data on blood pressure and tolerabilityBlood Pressure19976313179360003
   PubMedGoogle Scholar
• HanssonLZanchettiACarruthersSGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trialLancet19983511755629635947
   PubMed Web of Science ®Google Scholar
• [JNC-7] Joint National Committee VII Committee, National Heart, Lung, and Blood InstituteThe seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure2003 NIH Publication No. 03-5233; May 2003
   Google Scholar
• KearneyPMWheltonMReynoldsKGlobal burden of hypertension: analysis of worldwide dataLancet200536521223
   Web of Science ®Google Scholar
• KearneyPMWheltonMReynoldsKWorldwide prevalence of hypertension: a systematic reviewJ Hypertens200422111915106785
   PubMed Web of Science ®Google Scholar
• KhalilMEBasherAWBrownEJJRA remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patientsJ Am Coll Cardiol20013717576411401108
   PubMed Web of Science ®Google Scholar
• LevaCMariscalcoGFerrareseSThe role of zofenopril in myocardial protection during cardioplegia arrest: an isolated rat heart modelJ Card Surg20062144916426347
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGBainRPThe effect of angiotensin-converting-enzyme therapy on diabetic nephropathyN Eng J Med1993329145662
   PubMed Web of Science ®Google Scholar
• MalaccoEOmboniSAntihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination is superior to that of single componentsEur Heart J200526401
   Web of Science ®Google Scholar
• ManciaGGrassiGRationale for the use of a fixed dose combination in the treatment of hypertensionEur Heart J Supplements19991Suppl. LL1419
   Web of Science ®Google Scholar
• ManciaGZanchettiAAgabiti-RoseiEAmbulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophyCirculation1997951464709118514
   PubMed Web of Science ®Google Scholar
• MatarreseMSalimbeniATurollaEA11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilatBioorg Med Chem2004126031114738971
   PubMed Web of Science ®Google Scholar
• MoserMRationale for combination therapy in the management of hypertensionJ Clin Hypertens200356 Suppl.41725
   Google Scholar
• NapoliCSicaVde NigrisFSulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertensionAm Heart J2004148e515215814
   PubMed Web of Science ®Google Scholar
• ParatiGOmboniSMalaccoEon behalf of the Study GroupAntihypertensive efficacy of zofenopril and hydrochlorothiazide and their different combinations assessed by 24h ambulatory blood pressure monitoringJ Hypertens200523Suppl 2S309
   PubMedGoogle Scholar
• ReyesAJDiuretics in the therapy of hypertensionJ Hum Hypertens200216Suppl 1S788311986901
   PubMedGoogle Scholar
• ScribnerAWLoscalzoJNapoliCThe effect of angiotensin converting enzyme inhibition on endothelial function and oxidant stressEur J Pharmacol200348295914660009
   PubMed Web of Science ®Google Scholar
• SoubrierFAlhenc-GelasFHubertCTwo putative active centers in human angiotensin I-converting enzyme revealed by molecular cloningProc Natl Acad Sci U S A1988859386902849100
   PubMed Web of Science ®Google Scholar
• TotoRDRinnerSRamCVSACE inhibitors and target organ protection. An expanded role for these antihypertensive agents?Postgrad Med2004116111615323151
   PubMed Web of Science ®Google Scholar
• VaneJRThe history of inhibitors of angiotensin converting enzymeJ Physiol Pharmacol1999504899810639000
   PubMed Web of Science ®Google Scholar
• VasanRSLarsonMGLeipEPImpact of high-normal blood pressure on the risk of cardiovascular diseaseN Eng J Med200134512917
   PubMed Web of Science ®Google Scholar
• WangTJVasanRSEpidemiology of uncontrolled hypertension in the United StatesCirculation200511216516216157784
   PubMed Web of Science ®Google Scholar
• WestendorpBSchoemakerRGBuikemaHDietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarctionJ Renin Angiotensin Aldosterone Syst20045273215136971
   PubMed Web of Science ®Google Scholar
• WestendorpBSchoemakerRGvan GilstWHHydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenoprilEur J Pharmacol2005527141916310764
   PubMed Web of Science ®Google Scholar
• WetzelsGECNelemansPSchoutenJSFacts and fiction of poor compliance as a cause of inadequate blood pressure: a systematic reviewJ Hypertens20042218495515361751
   PubMed Web of Science ®Google Scholar
• [WHO–ISH] World Health Organization – International Society of Hypertension Writing Group2003. World Health Organization (WHO)–International Society of Hypertension (ISH) statement on management of hypertensionJ Hypertens20032119839214597836
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study InvestigatorsN Engl J Med20003421455310639539
   PubMed Web of Science ®Google Scholar
• ZanchettiAContribution of fixed low-dose combinations to initial therapy in hypertensionEur Heart J Supplements19991Suppl. LL5L9
   Web of Science ®Google Scholar
• ZanchettiAParatiGMalaccoEZofenopril plus hydroclorothiazide. Combination therapy for the treatment of mild to moderate hypertensionDrugs20066611071516789795
   PubMed Web of Science ®Google Scholar
• ZanchettiARuilopeLMAntihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from well controlled randomized trials?J Hypertens200220209511012359990
   PubMed Web of Science ®Google Scholar